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???????
??????????：Inflammatory cytokines and chemokines have been reported to play important roles in the 
pathogenesis of bronchial asthma. However, no criteria for the classification of ‘smoker’ and ‘atopic’ in bron-
chial asthma have been defined. In this study, we compared the levels of several cytokines found in the 
bronchoalveolar lavage （BAL） fluid of patients classified as having bronchial asthma.
???????：Cell subpopulations in BAL fluid were counted. BAL fluid levels of interleukin （IL）-4, -5, -13, 
-17, and -33 and RANTES （regulated on activation, normal T cell expressed and secreted were measured 
using a bead suspension array in 36 asthma patients （13 males, 23 females；mean age, 39.5±92.8 years） 
who were non-smokers, 18 asthma patients （11 males, 7 females；mean age, 30.7±2.7 years） who were ex 
or current smokers （Brinkman index （BI）：1−399）, and 10 asthma patients （9 males, 1 female；mean age, 
50.2±5.5 years） who were current heavy smokers （BI：≥ 400）. Relationships were assessed by Spearman’s 
rank correlation analysis.
???????：The number of lymphocytes in BAL cell subpopulations of non-smokers （25±7×103/ml） were 
significantly （p＜0.05） higher than those of heavy smokers （12±3×103/ml）. The number of neutrophils 
was significantly （p＜0.05） higher in heavy smokers （18±9×103/ml） than in non-smokers （4±2×103/ml）. 
Levels of IL-33 and RANTES were significantly （P＜0.05） higher in non-smokers （26.1±7.3 pg/ml and 
42.8±10.3 pg/ml, respectively） than in heavy smokers （13.7±4.5 pg/ml and 27.4±5.4 pg/ml, respectively）. 
In addition, the levels of IL-33 and RANTES in non-smokers were significantly （P＜0.05） higher in atopic 
asthma patients （33.0±9.8 pg/ml and 47.8±14.0 pg/ml, respectively） than in non-atopic asthma patients 
（9.1±3.8 pg/ml and 29.5±7.8 pg/ml, respectively）. A good correlation was noted between RANTES and 
lymphocytes （R＝0.365, P＜0.05） or IL-33 （R＝0.561, P＜0.05） in atopic asthma patients who were non-
smokers.
???????????：Differences in the cell types of BAL fluid, as well as in the levels of IL-33 and RANTES in 
asthma patients with or without smoking, might reflect pathogenesis.
???? ????： BAL fluid, IL-33, RANTES, asthma, smoker, atopy
??????????????????
BAL：bronchoalveolar lavage；RANTES：regu-
lated on activation, normal T cell expressed and 
secreted；BI：Brinkman index
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were ex or current smokers to determine whether a 
distinct profile of cell populations and the noted cytok-
ines exist in the phenotype and to evaluate the corre-
lations between BAL cell populations and cytokines.
???????
Patients
Patients enrolled in the study had undergone a med-
ical examination between 1999 and 2011 and endo-
bronchial fiber biopsy within one month before enroll-
ment. Diagnosis of mild or moderate bronchial asthma 
was clinically established on the basis of a consensus 
report21） and pathologically confirmed by endobronchi-
al biopsy. Subjects included 36 asthma patients who 
were non-smokers （13 males and 23 females；mean 
age, 39.5±2.8 years）, 18 who were ex or current mod-
erate smokers （Brinkman index （BI）：1−399；11 
males and 7 females；mean age, 30.7±2.7 years）, and 
10 who were current heavy smokers （BI：≥ 400；9 
males and 1 female；mean age, 50 .2±5.5 years）. Se-
rum total IgE was examined, and the pulmonary func-
tion test was performed in all enrolled patients （Table 
1）. 
None of the subjects had received oral steroid thera-
py or experienced acute bronchitis in the 4 weeks pri-
or to clinical sample collection. Patients with cancer in 
any organ and those suspected of malignancy were ex-
cluded from the study. Each atopic patient （26 non-
smokers, 13 moderate smokers, and 9 heavy smokers） 
tested positive （ ≥class 2） for Dermatophagoides fari-
nae, house dust mite, cat, or candida in sera detected 
by CAP-RAST （Phadia, Uppsala, Sweden）. Patients 
with chronic obstructive pulmonary disease （COPD） 
were excluded on the basis of diffusing capacity of CO 
and chest computed tomography findings.
The study protocol was approved by the Human 
Ethics Review Committees of Dokkyo Medical Univer-
sity, and a signed consent form was obtained from all 
subjects.
Bronchoalveolar lavage
Bronchoalveolar lavage （BAL） fluid samples were 
obtained from all subjects. BAL was performed as de-
scribed previously22） using a flexible fiberoptic bron-
choscope （Olympus 1T-200, Olympus, Tokyo, Japan） 
after local anesthesia of the upper airway with 4％ li-
????????????
Airway inflammation plays a central role in the 
pathogenesis of asthma. The large and medium air-
ways of patients with asthma show evidence of chronic 
inflammation, including leukocyte infiltrates in bronchi-
al tissue, excessive mucus production, epithelial dam-
age, basement membrane thickening, and smooth mus-
cle hypertrophy1 , 2）. The inflammatory infiltrates 
characteristically contain substantial populations of T 
cells, eosinophils, monocytes, and neutrophils. Asthma 
is associated with atopy and recruitment of eosinophils 
to the airways, which has led to the hypothesis that 
the pathogenesis of asthma is driven by a T helper 
（Th）2 response to inhaled antigens3,4）. Th2-type im-
munoregulatory cytokines play an important role in 
orchestrating immune and inflammatory processes5〜8）. 
In addition, RANTES （regulated on activation, normal 
T cell expressed and secreted, classified as a chemot-
actic cytokine or chemokine, is chemotactic for T cells, 
eosinophils, and basophils and plays an active role in 
recruiting leukocytes into inflammatory sites9,10）. IL-33 
is a recently described member of the IL-1 family 
which induces signaling via its receptor, ST211,12）. ST2 
is expressed abundantly on the surface of mast cells 
and Th2 cells12）. 
Despite the strength of the Th2-eosinophil para-
digm, some features of human asthma cannot be ex-
plained by this mechanism alone. For instance, neutro-
philic inflammation is commonly observed in bronchial 
biopsy of asthma patients, and the degree of neutro-
philia correlates significantly with asthma severity 13）. 
Previous studies have demonstrated that 50％ of asth-
ma cases are non-eosinophilic ─the predominant 
mechanism is neutrophil inflammation in the airway14）, 
which can be induced by IL-1, tumor necrosis factor 
（TNF）, and IL-1715〜17）. Furthermore, smoking also in-
duces neutrophilic airway inflammation, and relation-
ships have been established between smoking history, 
airway inflammation, and lung function in asthma pa-
tients who smoke18）. And IL-8 , interferon （IFN）-g , 
and TNFa  involves in pathogenesis of airway inflam-
mation in smoking asthma19,20）. 
In this study, we measured the BAL fluid levels of 
IL-4, -5, -13, -17, and -33 and RANTES in asthma 
patients who were non-smokers and in those who 
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BAL fluid of non-smoking asthma patients
P＜0.05） was observed between the nonstandardized 
and standardized albumin concentrations in BAL fluid 
of 7 patients with bronchial asthma （data not shown）. 
Consequently, the cytokine levels reported in the text 
are those of measured concentrations rather than 
those relative to albumin concentration. BAL fluid lev-
els of IL-4, -5, -13, -17, and -33 and RANTES were 
measured using a bead suspension array. Detection 
limits were 0.2 pg/ml, respectively.
Statistical analysis
All data are expressed as mean±standard error 
（SE） values. Differences between groups were com-
pared by one-way analysis of variance. Fisher’s PLSD 
test was used as the post hoc test. We also used Spear-
man’s rank correlation analysis to examine relation-
ships. Statistical analysis was performed using JMP 
software （Cary, NC）. Statistical significance was de-
fined by P＜0.05.
???????
Cell count in BAL fluid of asthma patients with or 
without smoking
Assessment of cell subpopulations （Fig. 1A） and cell 
number （Fig. 1B） in BAL fluid revealed that the num-
ber of total cells was significantly （p＜0.05） greater in 
current heavy smokers （301±59×103/ml） and ex or 
current moderate smokers （242±19×103/ml） than in 
non-smokers （144±19×103/ml）. Neutrophils were 
significantly （p＜0 . 05） more prevalent in current 
heavy smokers （18±9×103/ml） than in ex or current 
moderate smokers （1±1×103/ml） and in non-smok-
ers （4±2×103/ml）. On the other hand, the number of 
lymphocytes was significantly （P＜0.05） greater in 
docaine. Briefly, the bronchoscope was wedged for la-
vage into one of the subsegmental bronchi of the right 
middle lobe. BAL was performed three times using a 
50 ml aliquot of sterile physiologic saline solution. BAL 
fluid was passed through two sheets of gauze and then 
centrifuged at 500× g for 10 min at 4 ℃ before being 
centrifuged at 500× g for 5 min at room temperature, 
and the supernatant was stored at −80 ℃ for further 
quantification of non-cellular components. After wash-
ing twice with phosphate-buffered saline solution, cells 
were suspended with 10％ heat-inactivated fetal calf 
serum and counted using a hemocytometer. Differen-
tial cell counts were determined from cell suspensions 
displayed on slides using a cytocentrifuge （Cytospin 
2；Shandon Instruments；Sewickley, PA）. Cells were 
dried, fixed onto slides, and stained by the May-Grun-
wald-Giemsa method. A total of 200 cells were identi-
fied under a photomicroscope.
Measurement of IL-4, -5, -13, -17, and -33 and 
RANTES in BAL fluid
BAL fluid samples were concentrated using a Cen-
triprep-3 （Millipore Corporation；Billerica, MA）, 
which is used to concentrate low-molecular-weight 
components. The cut-off value for molecular weight 
was 3000 Da. In this procedure, magnification of con-
centration was calculated using the ratio of protein 
consistency in nonconcentrated BAL fluid to concen-
trated BAL fluid, which was measured by assay （DC 
protein Assay, Bio-Rad Laboratories, Hercules, CA）, 
and the original levels of cytokines were corrected 
with this ratio23）. Since BAL producer has a dilutional 
effect on cytokine recovery, measurement results are 
occasionally standardized to albumin. A good correla-
tion with IL-5 （R＝0.79, P＜0.05） and IL-33 （R＝0.78, 
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Age
（years）
Sex
（male/female）
B. I
Height
（cm）
Atopy
（＋/−）
IgE
（IU/ml）
％VC
（％）
FEV1.0
（％）
％DLCO
（％）
Non
Smoker
39.5±2.8 13/23 0 160.1±1.5
26/8
subjects
374±99 107.5±3.0 77.4±1.6 101.6±3.1
BI＝1-399 30.7±2.70 11/7 125.56±21.16 164.9±1.6 13/5 506±175.5 90.9±8.1 79.7±3.4 103.2±3.9
BI≧400 50.2±5.5 9/1 836±114.15 165.3±2.3 5/5 544±300. 99.9±14.1 72.6±5.9 97.3±8.0
Clinical characteristics of asthma patients who were non-smokers, ex or current moderate smokers （Brinkman index 
（BI）：1−399）, and current heavy smokers （BI：＞400）. Data are expressed as mean±SE values.
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????????　 Cell subpopulations （?） and cell number （?） in BAL fluid of asthma patients who are non-smokers （a）, 
ex or current moderate smokers （BI：1−399） （b）, and current heavy smokers （BI：≥ 400） （c）. Data are 
expressed as mean±SE values. P＜0.05 compared with non-smokers or moderate smokers. Eo, 
eosinophils；Ly, lymphocytes；Neu, Neutrophils；Mac, macrophages.
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els of RANTES were significantly （p＜0.05） higher in 
non-smokers than in ex or current moderate smokers 
（26.7±7.4 pg/ml）. 
IL-33 and RANTES concentrations in BAL fluid of 
atopic or non-atopic asthma patients and relationship 
with smoking
To determine the significance of the high levels of 
IL-33 and RANTES in non-smokers compared with 
smokers, we measured IL-33 and RANTES concentra-
tions in BAL fluid of atopic or non-atopic non-smokers 
（Fig. 3）. The levels of IL-33 and RANTES in non-
smokers were significantly （P＜0.05） higher in atopic 
asthma patients （33.0±9.8 pg/ml and 47.8±14.0 pg/
ml, respectively） than in non-atopic asthma patients 
（9.1±3.8 pg/ml and 29.5±7.8 pg/ml, respectively）. 
non-smokers （25±7×103/ml） than in ex or current 
moderate smokers （9±2×103/ml） and in current 
heavy smokers （12±3×103/ml）. There were no sig-
nificant differences in the number of eosinophils be-
tween smokers and non-smokers.
BAL fluid levels of IL-4, -5, -13, -17, and -33 and 
RANTES
We measured the levels of IL-4, -5, -13, -17, and 
-33 and RANTES in BAL fluid of asthma patients who 
were non-smokers, ex or current moderate smokers, 
and current heavy smokers （Fig. 2）. Levels of IL-4 , 
-5 , -13 , and -17 were similar between smokers and 
non-smokers. On the other hand, the levels of IL-33 
and RANTES were significantly （p＜0.05） higher in 
non-smokers （26.1±7.3 pg/ml and 42 .8±10.3 pg/ml, 
respectively） than in heavy smokers （8.9±4.9 pg/ml 
and 28.6±7.5 pg/ml, respectively）. In addition, the lev-
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????????　 BAL fluid levels of IL-4, -5, -13, -17, and -33 and RANTES in asthma patients who are non-smokers （a）, 
moderate smokers （BI：1−399） （b）, and heavy smokers （BI：≥ 400） （c）. Cytokines were measured 
using a bead suspension array. Detection limits were 0.2 pg/ml. Data are expressed as mean±SE values. P
＜0.05 compared with non-smokers.
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tant. The results suggest that the lymphocytes which 
infiltrate bronchial tissue play an important role in the 
pathogenesis of asthma and might be associated with 
IL-33 , induction of Th2 , RANTES, and the recruit-
ment of T cells into bronchial tissue.
Airway inflammation in allergic asthma is character-
ized by increased numbers of eosinophils and mast 
cells, hypersecretion of mucus, and activation of T 
cells 24,25）. Classically, the recruitment of Th2 lympho-
cytes, accompanied by the recruitment of eosinophils 
to the airways, has been considered integral to the 
pathogenesis of asthma26）. Eosinophils play an impor-
tant role in the pathogenesis of allergic airway inflam-
mation3,4）. Our results showed that the number of eo-
sinophils in BAL fluid was similar between asthma 
patients, irrespective of smoking status, suggesting 
that eosinophils play an important role in the induction 
Correlation between each cytokine and cell type in BAL 
fluid
Finally, we analyzed the correlations between the 
levels of IL-4, -5, -13, -17, and -33, RANTES, and cell 
type in BAL fluid using Spearman’s rank correlation 
test （Table 2）. A good correlation was noted between 
RANTES and lymphocytes （R＝0.365 , P＜0.05） and 
IL-33 and lymphocytes （R＝0.561, P＜0.05） in atopic 
asthma patients who were non-smokers （Fig. 4）. No 
significant correlations were observed between the 
levels of other cytokines and cell type.
??????????
The pathogenesis of allergic asthma has indicated 
the involvement of Th25〜8）. In this study, the finding 
of increased levels of IL-33 and RANTES in atopic 
asthma patients who were non-smokers is very impor-
32 DJMS
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???????　Sperman’s rank correlation
IL-4 IL-5 IL-13 IL-17 IL-33 RANTES
Macrophages −0.263 0.105 0.250 0.220 −0.248 0.073
Lymphocytes −0.185 0.330 0.067 0.272 −0.056 0.365 ＊
Neutrophils −0.118 0.264 0.037 0.050 −0.231 0.048
Eosinophils 0.143 0.317 −0.002 0.012 −0.202 0.038
IL-4 ─ −0.263 −0.184 0.034 0.014 0.249
IL-5 −0.263 ─ 0.099 0.125 0.077 −0.087
IL-13 −0.184 0.099 ─ 0.212 −0.093 −0.071
IL-17 0.034 0.125 0.212 ─ 0.060 0.253
IL-33 0.013 0.077 −0.093 0.060 ─ 0.561 ＊
RANTES 0.249 −0.087 −0.071 0.253 0.561 ＊ ─
Correlation between cytokines and differential cell counts.
＊＜0.05
BAL fluid of non-smoking asthma patients
eosinophils to the airways, has been considered inte-
gral to the pathogenesis of asthma5〜8）. IL-4 is a key 
cytokine in the development of allergic inflammation. 
IgE-dependent mast cell activation induced by IL-4 
has a pivotal role in the development of immediate al-
lergic reactions31）. An additional mechanism by which 
IL-4 contributes to airway obstruction in asthma is 
through the induction of mucin gene expression and 
the hypersecretion of mucus32）. IL-4 increases the ex-
pression of eotaxin and other inflammatory cytokines 
from fibroblasts that might contribute to inflammation 
and lung remodeling in chronic asthma33）. In general 
however, IL-4 in BAL is difficult to detect34）. Further-
more, although no IL-4 was detected in the present 
study, it has been shown to be important for allergic 
airway inflammation in the pathogenesis of asthma. 
IL-5 produced by Th2 cells and mast cells has long 
been associated with the cause of several allergic dis-
eases, including allergic rhinitis and asthma, wherein a 
large increase in the number of circulating, airway tis-
of allergic airway inflammations regardless of asthmat-
ic phenotype. On the other hand, several investigators 
have reported that neutrophil infiltration into bronchial 
and lung tissues plays an important role in the patho-
genesis of COPD and asthma in smokers27,28）. Our re-
sults revealed a similarly increased number of lympho-
cytes and neutrophils in asthma patients who were 
non-smokers and in heavy smokers, which is a similar 
finding to the above reports. In addition, the number 
of total BAL cells was increased in heavy smokers 
compared with those who were non-smokers. COPD is 
associated with a chronic inflammatory response, pre-
dominantly in the small airways and lung parenchyma, 
and is characterized by increased numbers of total 
cells, such as macrophages, neutrophils, and T lympho-
cytes29,30）. The present results suggest that the mecha-
nism of airway inflammation is similar between asthma 
patients with COPD and those who smoke.
Recruitment of Th2 lymphocytes, which secrete IL-
4, IL-5, and IL-13, accompanied by the recruitment of 
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????????　 Correlation between RANTES and lymphocytes 
and IL-33 and lymphocytes in atopic asthma 
pat i ents who were non-smokers . P＜0 . 0 5 
compared with lymphocytes or indiv idual 
cytokines. Correlations were determined by linear 
regression analysis between RANTES and 
lymphocytes or IL-33 and lymphocytes.
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tween asthma patients who smoke and those who 
were non-smokers.
IL-33 is produced by antigen- or infection-depen-
dent apoptotic or necrotic epithelial cells46,47）. IL-33 is 
activated in Th2 cells and eosinophils through the ST2 
receptor and is induced by Th2 cytokines, such as IL-
4 , IL-5 , and IL-1312）. RANTES can be produced by 
several inflammatory cells including T cells and mac-
rophages, and epithelial cells43〜45）. Moreover, RANTES 
is chemotactic for T cells, eosinophils, and basophils 
and plays an active role in recruiting leukocytes into 
inflammatory sites9,10）. In our study, a good correlation 
was seen between IL-33 and RANTES. In addition, 
there was a good correlation between RANTES and 
lymphocytes in BAL fluid of asthma patients who 
were non-smokers. This finding suggests that the cel-
lular source of this cytokine （RANTES） is bronchial 
epithelial cells. RANTES might also play an important 
role in recruiting lymphocytes for the pathogenesis of 
atopic asthma in non-smokers. On the other hand, no 
correlation was noted between individual cell popula-
tions, especially lymphocytes and IL-33 , indicating 
that IL-33 might be induced only slightly in Th2 cells 
existing in lymphocytes. In general, IL-5 correlated 
well with eosinophils in the BAL fluid of asthma pa-
tients48）. In our study, however, no correlation was 
noted between eosinophils and IL-5 in atopic asthma 
patients who were non-smokers and in those who cur-
rently smoked （data not shown）. This discrepancy 
was thought to be due to the effect of eotaxin, a CC 
chemokine strongly recruiting eosinophils49）. 
IL-17 acts as a potent mediator in delayed-type re-
actions by increasing chemokine production in various 
tissues to recruit monocytes and neutrophils to the site 
of inflammation50）. IL-17 is produced by Th cells51）. In 
our study, the levels of IL-17 were similar between 
non-smokers and current smokers, but the correlation 
between IL-17 and neutrophils was unclear. In gener-
al, IL-17 is chemotactic for neutrophils and plays an 
important role in the pathogenesis of asthma50,51）. This 
discrepancy was considered to be due to the involve-
ment of IL-8 and TNF-a  inducing chemotaxis to neu-
trophils19,20）. 
In conclusion, the effect of lymphocytes in asthma 
patients who were non-smokers and neutrophils in 
asthma patients who currently smoke might strongly 
sue, and induced sputum eosinophils has been ob-
served35,36）. Given the high concordance of eosinophils 
and, in particular, allergic asthma pathology, it is wide-
ly speculated that eosinophils have an important role 
in the pathology of this disease35,36）. IL-13 produced by 
inflammatory cells, especially Th2 cells, induces many 
features of allergic lung disease, including airway hy-
perresponsiveness, goblet cell metaplasia, and mucus 
hypersecretion, which all contribute to airway obstruc-
tion37 ,38）. In our study, the levels of IL-5 and IL-13 
were similar between non-smokers and ex or current 
smokers, likely because both interleukins play impor-
tant roles in the pathogenesis of asthma, regardless of 
smoking.
IL-33 is a recently described member of the IL-1 
family and induces signaling via its heterodimeric re-
ceptor, ST2, and the IL-1R accessory protein11,12）. ST2 
is abundantly expressed on the surface of mast cells 
and Th2 cells, and like IL-33 , ST2 is critical for the 
Th2 response12）. IL-33 can also promote the pathogen-
esis of asthma by inducing the production of Th2 cells, 
as demonstrated in studies in which blocking IL-33 
signaling suppressed the asthmatic response39 ,40）. In 
the present study, the increase in IL-33 was especially 
noticeable in atopic asthma patients who were non-
smokers, compared with non-atopic asthma patients 
who were non-smokers or those who were heavy 
smokers. This finding implies that the involvement of 
IL-33 in the pathogenesis of asthma may differ accord-
ing to the phenotype of asthma patients.
RANTES, which is generated by T lymphocytes, is 
one of the most extensively studied C-C chemokines 
in allergic inflammation41）. RANTES is likely to be im-
portant in airway inflammation because blocking anti-
bodies to RANTES inhibited airway inflammation in a 
murine model of allergic airway disease42）. A growing 
body of evidence suggests that many cell types pres-
ent in the airways of asthma patients, such as T cells, 
platelets, macrophages, fibroblasts, epithelial cells, 
and mast cells, have the capacity to generate RANT-
ES43〜45）, which directly supports the potential role of 
RANTES in asthma. In our study, the increase in 
RANTES was especially notable in asthma patients 
who were non-smokers, compared with ex or current 
smokers. This result suggests that the involvement of 
RANTES in the pathogenesis in asthma may differ be-
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mediate the induction of airway inflammation. Further-
more, although the involvement of cytokines in smok-
ing asthma was unclear, IL-33 and RANTES play an 
important role in the pathogenesis of atopic asthma pa-
tients who were non-smokers. The pathogenesis of al-
lergic airway inflammation may differ according to 
smoking status, including the number of cigarettes, the 
duration of smoking, and phenotype of asthma.
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